Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postpartum Zidovudine/Didanosine to Prevent Nevirapine Resistance
NCT00142337Phase 2Completed
- Sponsor
- Institut de Recherche pour le Développement
- Start
- Dec 2004
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of didanosine and zidovudine in human immunodeficiency virus infection (HIV), sponsored by Institut de Recherche pour le Développement. Primary endpoint: Proportion of patients with viral NNRTI mutations detectable during the 4 month follow-up. Started Dec 2004; status: completed.
02
Drugs
didanosinezidovudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00142337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00142337.